The Pharmacist’s Impact: Reimagined the Life Sciences Beyond COVID-19
Today's special guest is Susan Garfield, DrPH, Principal | Commercial Lead | Health Sciences and Wellness Sector with Ernst & Young LLP. Susan is an author on the study titled: Reimagined the Life Sciences Beyond COVID-19
Summary:
From payer-mix changes, to pricing and profitability concerns, COVID-19 has made the biopharma industry fraught with market and other pressures. However, these circumstances have also presented new opportunities, including accelerated adoption of digital tools and approaches. This was all made clear when we, in association with EY, surveyed 550+ biopharma executives - from R&D to commercial – to gain practical insights on the current state and long-term outlook for the industry.
This new free report ‘Beyond COVID-19: Life sciences reimagined’ highlights key findings from our analysis and is intended to help establish a framework for more patient-focused, sustainable care delivery post-crisis. Download this 30+ page report and:
See the impact of COVID-19 across the product lifecycle, highlighting commercial, HCP needs and relationships, marketing and the sales model, patient engagement, medical affairs and R&D – with one of the largest surveys of senior-pharma professionals during the pandemic
Hear from pharma leaders who are plotting the industry’s re-mergence strategies into the “new normal”
Benchmark your own response and experience to COVID-19 against hundreds of industry peers
Download this 30+ page report for free here.
Insights from industry leaders, include:
Karan Arora, Chief Commercial Digital Officer, AstraZeneca
Chetak Buaria, Global Head of Customer Engagement & Channel Evolution, Biopharma Global, Merck
Kabir Nath, President, Otsuka North America Pharmaceutical Business
Harmony Garges, CMO, ViiV Healthcare
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Summary:
From payer-mix changes, to pricing and profitability concerns, COVID-19 has made the biopharma industry fraught with market and other pressures. However, these circumstances have also presented new opportunities, including accelerated adoption of digital tools and approaches. This was all made clear when we, in association with EY, surveyed 550+ biopharma executives - from R&D to commercial – to gain practical insights on the current state and long-term outlook for the industry.
This new free report ‘Beyond COVID-19: Life sciences reimagined’ highlights key findings from our analysis and is intended to help establish a framework for more patient-focused, sustainable care delivery post-crisis. Download this 30+ page report and:
See the impact of COVID-19 across the product lifecycle, highlighting commercial, HCP needs and relationships, marketing and the sales model, patient engagement, medical affairs and R&D – with one of the largest surveys of senior-pharma professionals during the pandemic
Hear from pharma leaders who are plotting the industry’s re-mergence strategies into the “new normal”
Benchmark your own response and experience to COVID-19 against hundreds of industry peers
Download this 30+ page report for free here.
Insights from industry leaders, include:
Karan Arora, Chief Commercial Digital Officer, AstraZeneca
Chetak Buaria, Global Head of Customer Engagement & Channel Evolution, Biopharma Global, Merck
Kabir Nath, President, Otsuka North America Pharmaceutical Business
Harmony Garges, CMO, ViiV Healthcare
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Activity